INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Docket Number (Optional) Army 178	Application Number 0/772,704					
					Applicant(s) Tsokos						
	(Use several sheets if necessary)				Filing Date February 5, 2	2004	Group Art Unit				
By.			U.S.	. PATENT	DOCUMENTS						
EXAMINER	REP	DOCUMENT NUMBER	DATE		NAME CLASS		SUBCLASS		G DATE		
INITIAL	 				+	+	IF APPR	ROPRIATE			
<u> </u>	 		-	<u> </u>				 			
	<u> </u>			<u> </u>			<u> </u>				
<u> </u>											
			U.S. PATENT	: APPLICA	ATION PUBLICATIONS						
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DOCUMENT NUMBER DATE		NAME	CLASS	SUBCLASS		G DATE		
								II A	UPMALL		
			1			1					
			1		•,						
			+								
			FOREI	GN PATE!	NT DOCUMENTS						
	REF	DOCUMENT NUMBER	DATE		COUNTRY CLASS		SUBCLASS		nslation		
			+		1 2	+	YES NO				
								<u> </u>	<u> </u>		
			'								
				i							
				- 		T					
			OTHER DO				Pertinent Pages, Etc		.ـــــــــــــــــــــــــــــــــــــ		
JDS		Tenbrock, " Antisense of patients with systemic l	Tenbrock, "Antisense cyclic adenosine 5'-monoshosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus", Jour. of Immun. vol. 169, no. 8, 15 Oct. 2002, pages 4147-4152								
JDS Database WPI, & JP 11 123082 Abstract		Database WPI, sect. Ch & JP 11 123082 A, 11 N Abstract	ı, Week 199929, Ser Vlay 1999,	rwent PUI	blications Ltd., London,	GB; Class Bo	4, AN 1999-3405	518, XPOC	J22904		
EXAMINE	R				DATE CONSIDERED						
EXAMINEI not consider	R: Initis	al if citation considered, whether clude copy of this form with next	or not citation is in c	:onformanc	ce with MPEP Section 609;	Draw line thro	ugh citation if not	in conform	ance and		

Form PTO-A820 (also form PTO-1449) P09A/REV05

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

		_							
				Docket Number (Optional) Army 178	Application Number 10/772,704				
	INF		ATION DISCLOSURE CITATION	Applicant(s) Tsokos	10///2,/04				
			(Use several sheets if necessary)	Filing Date	Group Art Unit				
				February 5, 2004					
*EXAMINER OTHER DOCUMENTS (Including Author, T									
JDS			Yoshimoto Keiko et al., "Antisense repression of TCR zeta chain alters cell proliferation and IL-2 production in Molt-4 cell line.", Arthritis and Rheumatism, vol. 42, no. 9, SUPPL., Sept. 1999, pages \$95 XP008034010 &63rd annual scientific meeting of the American College of Rheumatology and the 34th annual scientific; Boston, Mass., Nov. 13-17, 1999 Abstract 146						
			Solumou E E et al. "Molecular basis of deficient IL- Journal of Immunology (Baltimore, MD 1950) 15 M	-2 production in T cells from patients farch 2001, vol. 166, no. 6., pages 421	with systemic lupus erythematosus." 6				
			Liossis, et al. "Altered prttern of TCR/CD3-mediate lupus erythematosis" Journal of Clinical Investiga	ation, vol. 101, no. 7, 4/1/98, pages 144	8-1457.				
kamm erytho			kammer et al., "Abnormal T lymphocyte signal trar erythematosus." Cruuent Directoins In Autoimmun	nsduction in systemic lymphocyte sign nity. 2002, vol. 5, 2002, pages 131-150.	al transduction in systemic lupus				
			Herndon, et al., "Direct transfer of p65 into T lymp levels of interleukin-2 promoter activity, Clinical In	phocytes from systemic iupus erythems nmunology (Orlando, FL) May 2002.	atosus patients leads to increased				
			Database Biosis 'Online! Biosciences Information So the T-cell: Signaling defects and novel prospects for Database accession No. PREV2003300292284. Abst	ervice Philadelphia, PA US; May 2003 r the treatment of SLE." tract	3 (2003-05), Tsokos et al, "Re2wiring				
\downarrow			Database medline Online, US National Library of Medicine, Bethesda, MD, July 2003, Nambiar Madhussodana, et al, "Reconstitution of Deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with syt=stemic lupus erythematosus." abstract &Arthritis and Rheumatism., Jul 2003, vol. 48, no. 7, July 2003, pges 1948-1955.						
				:					
EXAMINER /James Schultz/			/James Schultz/	DATE CONSIDERED 08/16	/2006				
*EXAMI	NER: In	itial if c	itation considered, whether or not citation is in conformation to applicant.	nce with MPEP Section 609; Draw line thr	ough citation if not in conformance and				

					Army 178 Application Number /C / 772, 764						
) S - 02/	83 /9	884	TION DISCLOSURE	CITATION		Applicant(s) Tsokos, et al.					
		(OSC SCIETUI SICEIS Y IICCESSU	.,,		Filing Date 2 5 04	Group Art Unit				
					U.S. PAT	ENT DOCUMENTS					
•EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
						-					
		 									
		\vdash		 							
	_	 			-						
		-					 				
		 	<u> </u>							•	
		-									
		 		<u> </u>							
		├					 	 			
		-					 			•	
		1		<u> </u>	FOREIC	N PATENT DOCUMENTS	1		L		
					POREIG	COUNTRY	CLASS	SUBCLASS	Translation		
	REF	-	DOCUMENT NUMBER	DATE	<u> </u>	COUNTRY	CLASS	SUBCLASS	YES	NO	
		ļ			ļ					_	
			. 0		<u> </u>				ļ		
		ļ		100	ļ				<u> </u>		
				ļ <u>.</u>	ļ						
							<u></u>				
			ION Y	100/01 - 45 -		DOCUMENTS (Including	Author, Title,	Date, Pertinent Pa	iges, Etc.)	e cuc	
JDS		A	Clin Immunol. 2002 May: 103(2): 145-53, Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity, Herndon, Juang, Solomou, Rothwell, Gourley, Tsokos, WRAIR								
ъs		B .	Journal of Immunology, (2002) NF-kB Regulates the Expression of the Human Complement Receptor 2 Gene, Tolnay.								
EXAMINE	EXAMINER /James Schultz/				DATE CONSIDERED	08/16	08/16/2006				
EXAMINE considered	R: Inii	ial if ci de copy	tation considered, whether	or not citation is in munication to app	conforman	ce with MPEP Section 609; D	raw line thro	igh citation if not	in conforma	nce and not	
L											

OF